← Home
The Prof G Pod with Scott Galloway · September 8, 2026 · 48m

China Decode: What's at Stake Ahead of Trump and Xi's September Meeting, and China's Biotech Surge

Alice Han, James Kynge, Ruby Wang

Alice Han and James Kynge preview President Trump and President Xi’s September 24 meeting in Washington, set against a flurry of Xi’s diplomatic activity and shifting trade leverage around rare earths, soybean purchases, and the AI arms race. Then, Ruby Wang joins to discuss China’s biotech boom — how faster, cheaper clinical trials and billions in licensing deals have turned the country into a global pharma challenger, and what it means for U.S. competitiveness. A timely look at the broader US-China rivalry beyond the trade deficit.

This summary was generated from show notes and public descriptions, not from a full transcript review. Details may contain inaccuracies.

Highlights

•
The September Trump-Xi Meeting: Shifting Leverage Through Trade, Rare Earths, and Soybeans
Han and Kynge preview the upcoming Washington meeting, analyzing how soybean purchases, rare earth exports, and broader trade dynamics are reshaping the leverage between the U.S. and China ahead of the talks.
ClaudeChatGPTGemini
•
Does AI Dominance Matter More Than the Trade Deficit?
The discussion raises the question of whether the U.S. is misallocating attention by fixating on trade balances when the real competition with China may be for control of artificial intelligence.
ClaudeChatGPTGemini
•
China's Biotech Transformation: From Follower to Global Licensing Power
Ruby Wang outlines how China’s pharmaceutical sector has rapidly advanced since 2010, now conducting faster, cheaper clinical trials and signing billions in global licensing deals, challenging U.S. pharma’s competitive edge.
ClaudeChatGPTGemini

References

■
China Cure: The Rise of a Biotech, AI Medicine and Global Health Superpower — Ruby Wang — subject of the interview
Was this useful?